GLP-1 agonists modestly improved left ventricular ejection fraction by 4.4% compared to placebo (95% CI 1.36-7.44, P=0.005) in heart failure patients, with no significant effect on BNP levels.
Meta-Analysis
Do GLP-1 agonists improve markers of cardiac function such as LVEF and BNP in patients with heart failure?
GLP-1 agonists provide a modest improvement in left ventricular ejection fraction in heart failure patients but do not significantly improve BNP levels.
Effect estimate: Mean difference 4.4% (95% CI 1.36-7.44)
p-value: p=0.005
We conducted a meta-analysis of the existing literature of the therapeutic effects of using GLP-1 agonists to improve the metabolism of the failing heart. Animal studies showed significant improvement in markers of cardiac function, such as left ventricular ejection fraction (LVEF), with regular GLP-1 agonist infusions. In clinical trials, the potential effects of GLP-1 agonists in improving cardiac function were modest: LVEF improved by 4.4% compared to placebo (95% C.I 1.36-7.44, P = 0.005). However, BNP levels were not significantly altered by GLP-1 agonists in heart failure. In two trials, a modest increase in heart rate by up to 7 beats per minute was noted, but meta-analysis demonstrated this was not significant statistically. The small number of studies plus variation in the concentration and length of the regime between the trials would limit our conclusions, even though statistically, heterogeneity chi-squared tests did not reveal any significant heterogeneity in the endpoints tested. Moreover, studies in non-diabetics with heart failure yielded conflicting results. In conclusion, the use of GLP-1 agonists has at best a modest effect on ejection fraction improvement in heart failure, but there was no significant improvement in BNP levels in the meta-analysis.
Munaf et al. (2012) conducted a meta-analysis in Heart Failure. GLP-1 agonists vs. Placebo was evaluated on Left ventricular ejection fraction (LVEF) (Mean difference 4.4%, 95% CI 1.36-7.44, p=0.005). GLP-1 agonists modestly improved left ventricular ejection fraction by 4.4% compared to placebo (95% CI 1.36-7.44, P=0.005) in heart failure patients, with no significant effect on BNP levels.